ArticleCurrent pharmacology reports2015
Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis.
Article in Current pharmacology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Association Between Metformin Use and Risk of Lung Cancer in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.Cancer reports (Hoboken, N.J.) · 2026 · on this mapPooled it
- Box Behnken optimization of cubosomes for enhancing the anticancer activity of metformin: Design, characterization, and in-vitro cell proliferation assay on MDA-MB-231 breast and LOVO colon cancer cell lines.International journal of pharmaceutics: X · 2023Article
- Review
- A ROS/Akt/NF-κB Signaling Cascade Mediates Epidermal Growth Factor-Induced Epithelial-Mesenchymal Transition and Invasion in Human Breast Cancer Cells.World journal of oncology · 2022Article
- Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.Cancer letters · 2021Article
- Enhanced antitumor activity of doxorubicin by naringenin and metformin in breast carcinoma: an experimental study.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Metabolic pathways in obesity-related breast cancer.Nature reviews. Endocrinology · 2021Review
- The Effects of NT-1044, a Novel AMPK Activator, on Endometrial Cancer Cell Proliferation, Apoptosis, Cell Stress andFrontiers in oncology · 2021Article
- Targeting Glucose Transporters for Breast Cancer Therapy: The Effect of Natural and Synthetic Compounds.Cancers · 2020Review
- Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality.Cancers · 2019Review
- Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.Breast cancer research and treatment · 2019Article
- Metformin and Breast Cancer: Molecular Targets.Journal of mammary gland biology and neoplasia · 2019Review
- High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells.Biomolecules · 2019Article
- Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.Breast cancer research : BCR · 2018Article
- Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes.Experimental and therapeutic medicine · 2017Article
- Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis.Therapeutic advances in medical oncology · 2017Article
- Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models.Oncotarget · 2017Article
- Fat, Calories, and Cancer.Cancer research · 2016Article
- Metformin for cancer and aging prevention: is it a time to make the long story short?Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
There is increasing interest in metformin's effects on the development, treatment and/or progression of breast cancer. This emerges from observational studies that diabetic women treated with metformin in comparison to other antidiabetic compounds had lower breast cancer incidence and/or mortality rates. The mechanism of action is considered to be activation of hepatic AMPK resulting in reduced gluconeogenesis. Calorie restriction, which consistently reduces mammary tumorigenesis in rodents, is also thought to act through this pathway leading to the hypothesis that metformin's anticancer effects are mediated in a similar fashion. Here we review the literature evaluating metformin's anticancer effects in relation to breast/mammary tumorigenesis. We include clinical observations, as well as studies utilizing rodent models and mammary cell lines. In addition to the anticancer effect of metformin mediated through the AMPK pathway, additional mechanisms of action that directly target tissues have been identified including effects on stem cells, apoptosis, STAT3 and HER2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.